Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Exploratory Study of the Safety and Preliminary Efficacy of Danicamtiv in Stable Ambulatory Participants With Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants or Other Causalities

Next Previous
Trial Profile

An Open-Label, Exploratory Study of the Safety and Preliminary Efficacy of Danicamtiv in Stable Ambulatory Participants With Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants or Other Causalities

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Danicamtiv (Primary)
  • Indications Dilated cardiomyopathy
  • Focus Adverse reactions; Proof of concept
  • Sponsors Bristol-Myers Squibb; MyoKardia

Most Recent Events

  • 06 Jan 2026 According to Kardigan media release, results from this trial were presented at the American Heart Association Scientific Sessions 2025.
  • 29 Sep 2025 According to Kardigan media release, the company announced that positive Phase 2a clinical trial data were presented in a late-breaking oral session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025 and simultaneously published in The Journal of the American College of Cardiology (JACC).
  • 29 Sep 2025 Results published in the Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top